We have cloned HERG USO , a C-terminal splice variant of the human ether-à -go-go-related gene (HERG), the gene encoding the rapid component of the delayed rectifier (I Kr ), from human heart, and we find that its mRNA is ϳ2-fold more abundant than that for HERG 1 (the originally described cDNA). After transfection of HERG USO in Ltk ؊ cells, no current was observed. However, coexpression of HERG USO with HERG 1 modified I Kr by decreasing its amplitude, accelerating its activation, and shifting the voltage dependence of activation 8.8 mV negative. As with HERG USO , HERG ⌬C (a HERG 1 construct lacking the C-terminal 462 amino acids) also produced no current in transfected cells. However, I Kr was rescued by ligation of 104 amino acids from the C terminus of HERG 1 to the C terminus of HERG ⌬C , indicating that the C terminus of HERG 1 includes a domain (<104 amino acids) that is critical for faithful recapitulation of I Kr . The lack of this C-terminal domain not only explains the finding that HERG USO does not generate I Kr but also indicates a similar mechanism for hitherto-uncharacterized long QT syndrome HERG mutations that disrupt the splice site or the C-terminal. We suggest that the amplitude and gating of cardiac I Kr depends on expression of both HERG 1 and HERG USO .
We have cloned HERG USO , a C-terminal splice variant of the human ether-à -go-go-related gene (HERG), the gene encoding the rapid component of the delayed rectifier (I Kr ), from human heart, and we find that its mRNA is ϳ2-fold more abundant than that for HERG 1 (the originally described cDNA). After transfection of HERG USO in Ltk ؊ cells, no current was observed. However, coexpression of HERG USO with HERG 1 modified I Kr by decreasing its amplitude, accelerating its activation, and shifting the voltage dependence of activation 8.8 mV negative. As with HERG USO , HERG ⌬C (a HERG 1 construct lacking the C-terminal 462 amino acids) also produced no current in transfected cells. However, I Kr was rescued by ligation of 104 amino acids from the C terminus of HERG 1 to the C terminus of HERG ⌬C , indicating that the C terminus of HERG 1 includes a domain (<104 amino acids) that is critical for faithful recapitulation of I Kr . The lack of this C-terminal domain not only explains the finding that HERG USO does not generate I Kr but also indicates a similar mechanism for hitherto-uncharacterized long QT syndrome HERG mutations that disrupt the splice site or the C-terminal. We suggest that the amplitude and gating of cardiac I Kr depends on expression of both HERG 1 and HERG USO .
The long QT syndrome is a disorder characterized by prolongation of the QT interval as a result of unusually slow repolarization of the cardiac action potential (1, 2) . One variant, LQT2, 1 is caused by mutations in the human ether-à -go-gorelated gene (HERG). Heterologous expression of HERG results in a current with the physiologic and pharmacologic properties of I Kr (3, 4) . These properties include strong inward rectification that is now recognized to be determined by the ultra-rapid inactivation that the channel undergoes with depolarization (4 -8) and by sensitivity to I Kr -specific methanesulfonanilide blockers, such as dofetilide (4, 9) . Importantly, HERG mRNA is detected at high abundance in human heart (10) , and I Kr has been recorded in human atrial and ventricular myocytes (11, 12) .
LQT2-associated HERG mutations in the pore of the channel display reduced or no I Kr (13) and, when expressed with wildtype cRNA, a dominant negative effect has been observed, implying that heteromeric (wild-type ϩ mutant) channel assembly occurs. Heteromeric assembly of physiologically occurring splice variants has also been suggested by the finding that an N-terminal splice variant of the human gene (or of the murine homolog mERG) itself resulted in no current in Xenopus oocytes, but when coexpressed with wild-type cRNA, I Kr with rapid activation and deactivation (typical of that observed in heart) was observed (14, 15) .
The initial identification of HERG mutations as a cause of LQT2 included a mutation in the 3Ј-region of the gene, which is predicted to result in disruption of a splice site and truncation of the C-terminal region of the protein (10) . However, it is not clear how this mutation disrupts I Kr function because the membrane-spanning segments, as well as the N-terminal region, which has been reported to be necessary for assembly of multiple K ϩ channel subunits into functional channels (16, 17) , are present. One possible mechanism is disruption of a putative cyclic nucleotide binding (CNB) domain within which the splice site is located. This domain was identified with the initial cloning of HERG (18) , but its functional role has not yet been elucidated, and cardiac I Kr has been reported to be unaffected by protein kinase A-dependent intracellular signaling (19) . Because this domain is disrupted in the C-terminal LQT2 mutation, it is conceivable that it plays a role in recapitulation of I Kr . However, a recent report of the genomic structure of HERG and analysis of additional LQT2 families raises the possibility that a more C-terminal region is actually required. This report included seven new mutations predicted to result in C-terminal truncations of HERG (20) , with a number 3Ј to the CNB domain; the one most 3Ј was predicted to result in truncation of the 3Ј 158 amino acids of the HERG protein. Thus, it remains unknown whether the CNB domain is required for recapitulation of I Kr . Recent studies with other potassium channels have raised the possibility that C-terminal regions are required for recapitulation of current, through mechanisms that have yet to be firmly established (21) (22) (23) .
In this report, we describe the isolation of a HERG C-terminal splice variant, which we call HERG USO , and its localization and functional characterization. These studies demonstrated that I Kr can be recapitulated even when the putative CNB domain is disrupted and have led to the identification of a 104-amino acid domain, present in the C terminus of HERG but absent in HERG USO , which appears essential for the recapitulation of I Kr in a heterologous expression system. This finding not only points to another potential mechanism for regulation of I Kr in vivo but also explains how C-terminal mutations in HERG can cause LQTS.
EXPERIMENTAL PROCEDURES
Library Screening-1 ϫ 10 6 plaques of a human ventricular cDNA library (a gift of Drs. Michael Tamkun and Sarah England) in Zap II (Stratagene, La Jolla, CA) were screened using standard techniques (24) under high stringency conditions. The probe consisted of a PCR fragment that covers nucleotides 1766 -3469 of the originally reported HERG, which here we term HERG 1 . In this report, nucleotide numbering starts at the translational start site of HERG.
RNase Protection-RNA was isolated for quantitation from samples of normal human left ventricle using the acid-phenol method of RNA extraction of Chomczynski and Sacchi (25) . In order to determine whether HERG USO mRNA was expressed in the human heart, we designed two probes, both overlapping the splice site at nt 2398, which we used in RNase protection analyses. A 104-nt probe for cyclophilin was used as an internal standard to normalize for equal RNA concentration across the lanes. RNase protection was performed as described previously (26) . The gels were dried and exposed to x-ray film as well as to a PhosphorImager (Molecular Dynamics) to quantitate relative band intensities.
Plasmid Construction-Clone pHERG 1 was constructed by excising the HindIII/EcoRI fragment of HERG 1 from the pSP64 vector (a gift from Mark Keating, University of Utah) and ligating it via its EcoRI site at the 3Ј-end into the EcoRI-digested mammalian expression vector pSI (Promega, Madison, WI) followed by treatment with Klenow and a second blunt-end ligation step.
Clone pHERG USO was constructed by first ligating the 3Ј-terminal XhoI/EcoRI fragment of phage isolate ⌽-D (Fig. 1) into the XhoI/EcoRIdigested pSI vector to generate clone pSKF104. The EcoRI site corresponds to the 3Ј-terminus of the isolate ⌽-D, whereas the XhoI site corresponds in location to the XhoI site at nt 2089 of HERG 1 . The resulting clone SKF104 was then digested at its 5Ј-end with XhoI and reconstituted at the N terminus using the HindIII/XhoI fragment of HERG 1 , which consists of the 2089 5Ј-most nt of the HERG 1 coding sequence. The initial Xho ligation was followed by treatment with Klenow and a second blunt-end ligation step to circularize the plasmid generating pHERG USO .
Clone pHERG ⌬C was constructed by excising the HindIII/XhoI fragment of HERG 1 from the pSP64 vector and ligating its 3Ј-end into XhoI-digested pSI followed by creation of blunt ends at the 5Ј-end using Klenow and a second, blunt-end ligation step. To control for possible mutations during growth in bacterial cells or other cloning artifacts, plasmid pSKH40 was created by excising the XhoI/EcoRI fragment of pHERG USO and replacing it with the XhoI/EcoRI fragment of HERG 1 in pSP64. This replaces the HERG USO 3Ј-terminus with that of HERG 1 , in effect reconstituting the original pHERG 1 clone.
Clone pHERG ⌬Cϩ104 was created by generating a PCR fragment corresponding to nt 3052-3366 of HERG with XhoI linkers at the termini and a stop codon (TAG) incorporated into the reverse primer. The forward primer was 5Ј-GGACTCGAGC CCACCCCCAG CCTCCT-CAAC ATCCC-3Ј. The reverse primer was 5Ј-CTACTCGAGC TAC-GGGGGCA GCTCCTCACA CGCCATG-3Ј. XhoI recognition sites are italicized and boldface, and the stop codon is double underlined. The PCR fragment was digested with XhoI followed by gel purification and ligation into XhoI-digested pHERG ⌬C . Resulting clones were sequenced to identify those containing the PCR fragment in the correct orientation. The reading frame of the PCR fragment is conserved.
All plasmids described were partially sequenced across vector/insert junctions and across junctions generated by ligation steps and were further characterized by restriction pattern analysis.
Cell Culture and Transfection-Ltk Ϫ cells were cultured in DMEM supplemented with 10% horse serum. The cells were transfected using the LipofectAMINE method according to the manufacturer's instructions (Life Technologies, Inc.). Green fluorescent protein was coexpressed to assess the transfection efficiency and to identify expressing cells for voltage-clamp analysis (27) . The transfection mixture included 1-10 g of HERG isoforms or chimeras (in pSI), 1 g of green fluorescent protein/pRcCMV, and 12-30 l of LipofectAMINE reagent in 0.5 ml of serum-free DMEM for 6 h, after which the standard medium was restored. The cells were removed from the dish 24 h later by a brief trypsinization, washed twice in standard medium, and stored for use within the next 12 h. Parallel nontransfected cultures or cells transfected with green fluorescent protein alone (mock transfection) served as controls.
Electrophysiology Methods-Whole cell voltage clamp (28) was used to record currents in transfected cells displaying green fluorescence, as described previously (4) . Experiments were performed at room temperature (21-23°C) and sampled at 1-10 kHz after antialias filtering at half or less of the sampling frequency. Specific protocols are specified in the text and figure legends. The cycle time between pulses was Ն20 s to accommodate pulse durations and slow I Kr activation (especially below ϩ10 mV). HERG activation kinetics were slow below Ϫ20 mV (see under "Results"), and only passive linear leak (Ͼ1 G⍀) was observed during short (100 ms) depolarizations between Ϫ90 and Ϫ40 mV; therefore, least squares fits to these data were used for passive leak correction. Mono-and multiexponential functions were fit to activating current using least squares methods.
The intracellular pipette filling solution contained 110 mM KCl, 10 mM HEPES, 5 mM K 4 BAPTA, 5 mM K 2 ATP, and 1 mM MgCl 2 , adjusted to pH 7.2 with KOH (final intracellular [K ϩ ], ϳ145 mM). The bath solution contained 145 mM NaCl, 4 mM KCl, 1.8 mM CaCl 2 , 1 mM MgCl 2 , 10 mM HEPES, and 10 mM glucose, adjusted to pH 7.35 with NaOH. Dofetilide was provided by Pfizer Central Research. All other compounds were obtained from Sigma.
RESULTS
Isolation of HERG USO -Three clones, designated ⌽-D, ⌽-L, and ⌽-M, were isolated by screening the human heart library. Isolate ⌽-L had a partial cDNA insert that corresponded to nucleotides 3064 -3886 of HERG 1 , i.e. the 3Ј -terminal 138 amino acids plus the 3Ј-untranslated region of HERG 1 (18) (Fig. 1) . ⌽-M and ⌽-D also contained partial cDNAs. The 5Ј-end of ⌽-M was located at HERG 1 nt 1267, and that of ⌽-D was located at HERG 1 nt 813. Both clones were identical to HERG 1 up to HERG 1 nt 2398, the previously reported splice site (10) . Following the splice junction in both isolates were 750 nt of a novel sequence that we designated USO. Because clone ⌽-M appears to be a subset of clone ⌽-D, we restricted our subsequent analysis to ⌽-D.
The reading frame of HERG 1 as it continues into the USO stays open for another 264 nt (88 amino acids). USO appears to be partially made up of sequences previously thought to be intronic because a sequence corresponding to a previously reported intronic primer (10) , located between exons 9 and 10 in the mouse gene (15) , is located 30 nt 3Ј to the splice junction at position 2398.
RNase Protection-Probe E75-1 is predicted to protect a fragment of 228 nt if the HERG 1 -type splice junction is represented within the mRNA and a fragment of 154 nt if a splice event other than HERG 1 (e.g. HERG USO ) occurs (Fig. 2) . Conversely, probe E114 is predicted to protect a 191-nt fragment if HERG USO mRNA is present and a smaller (154 nt) fragment if another splice variant is present. Fig. 2 shows that HERG USO is present at ϳ2-fold higher levels in human heart than HERG 1 (range, 1.7-2.1-fold, n ϭ 4). Similar findings were obtained using human left ventricle, atrium, midmyocardium, uterus, cultured human lymphocytes, and, on longer exposure, brain. Further evidence that HERG USO mRNA is expressed in other tissues is provided by the results of a Basic Local Alignment Search Tool (BLAST) (29) search of GenBank TM using the USO sequence. This identified two expressed sequence tags from human fetal liver/spleen (R07336 and R07383) matching HER-G USO . R07383 is 395 nt and matches the HERG USO open reading frame starting 42 nt 3Ј to the 2398 splice junction and extending beyond the HERG USO stop codon, whereas R07336 is 311 nt and matches HERG USO in its 3Ј-untranslated region.
Functional Characterization of HERG USO -When pHERG 1 was transfected (Fig. 3, left panels) , typical I Kr was observed. A brief hyperpolarizing pulse to remove inactivation (4 -8) resulted in a characteristic augmentation of current, which then rapidly reinactivated, at positive potentials (Fig. 3C, left) . By contrast, no current was observed, even after a hyperpolarizing pulse, following transfection with pHERG USO alone. When pHERG 1 and pHERG USO were cotransfected in equimolar concentrations, I Kr with amplitude and gating properties very similar to those observed with transfection of pHERG 1 alone was observed. As shown in Fig. 3 (right panels) , when a 10-fold excess of pHERG USO was transfected with pHERG 1 , the current remained I Kr -like. However, it is apparent from Fig. 3 (right) that the current in the latter cotransfection experiments was smaller than that observed with pHERG 1 alone and displayed faster and more negative voltage dependence of activation.
These findings are summarized in Fig. 4 . The midpoint of activation was shifted 8.8 mV negative (Fig. 4A) . After depolarizing clamp steps from Ϫ50 to Ϫ40 to ϩ60 mV (Fig. 3, A and  B) , activating currents were 3-4-fold larger with pHERG 1 alone (Fig. 4B) . When inactivation was removed by a brief hyperpolarization (Fig. 3C) , current with pHERG 1 alone was 513 Ϯ 137 pA/pF (n ϭ 6) versus 203 Ϯ 40 pA/pF (n ϭ 7, p ϭ 0.03) with cotransfection. Fits to activating current required biexponential functions in the Ϫ10 to ϩ30 mV range, and a monoexponential function was sufficient in the ϩ40 to ϩ60 mV range. In either case, it is apparent from Fig. 4C that activation was consistently ϳ3-5-fold faster with cotransfection over all voltages tested. By contrast, the time constants for deactivation were similar in the two sets of experiments.
The fact that no current was observed when pHERG USO was expressed alone was somewhat unexpected, because the protein domains of the N terminus and the transmembrane-spanning region, including the voltage sensor and pore region, are all intact. To guard against the possibility of sequence rearrangements during the passage of plasmid constructs in bacterial hosts resulting in changes that would account for the lack of current observed with expression of pHERG USO and pHERG ⌬C , we conducted experiments to rescue HERG 1 from pHERG USO . A full-length HERG 1 plasmid, pSKH40, was generated from pHERG USO by replacing the HERG USO C terminus with the C terminus from HERG 1 . Expression of pSKH40 resulted in I Kr .
We next considered the possibility that the protein domain encoded by the USO might exert an inhibitory effect on channel expression or function. To test this idea, we generated a Cterminal truncation mutant of HERG 1 that lacks the C-terminal 461 amino acids, including both the CNB domain and the USO. This construct, pHERG ⌬C (Fig. 1) , terminates 32 amino acids past the S6 domain at a unique XhoI site (nt 2089) of HERG 1 . However, with transfection of pHERG ⌬C , no currents were recorded. We therefore concluded that a protein domain encoded by the region 3Ј of the splice junction at nt 2398 (i.e. within residues 800 -1159) of HERG 1 is required for the functional expression of I Kr . The CNB domain homolog present in HERG 1 is truncated in HERG USO and completely missing in HERG ⌬C . Our next step was therefore to determine whether pHERG ⌬Cϩ104 , a construct totally lacking this domain but preserving the N terminus (Fig. 1) , could rescue expression of I Kr . After Ltk Ϫ cells were transfected with pHERG ⌬Cϩ104 , a current with most features of I Kr was recorded (Fig. 5) . Although the shows traces elicited by depolarizing clamp steps from ϩ30 to ϩ60 mV, and panel B shows traces elicited from Ϫ60 to ϩ20 mV. Panel C shows current tracings before and after brief (5-60 ms) hyperpolarizing steps to Ϫ100 mV after a 5-s prepulse to ϩ40 mV.
FIG. 2.
RNase protection of mRNA isolated from human heart. As described in the text, riboprobes complementary to HERG 1 (E75-1) and to HER-G USO (E114) sequences overlapping the splice junction at nt 2398 were used; in both cases, HERG USO mRNA was 2-3-fold more abundant than that for HERG 1 . kinetics of activation and deactivation as well as the V 1/2 appeared to be somewhat different from those of HERG 1 and the tails were somewhat smaller, the expressed current still activated and deactivated rapidly (Fig. 5A ) and displayed prominent inward rectification (Fig. 5B) and a large very rapidly inactivating current at positive potentials after a hyperpolarizing step (Fig. 5C) . The current was suppressed by 1 M dofetilide. DISCUSSION We have identified here a 3Ј-splice variant of HERG that is more abundantly expressed in human heart and other tissues than the originally reported mRNA. However, expression of the variant in mammalian cells did not give rise to potassium current, although coexpression with HERG 1 showed a striking effect on the amplitude and activation of I Kr , suggesting that HERG USO can coassemble with HERG 1 to modify its gating. The mechanism underlying the failure of HERG USO alone to generate current is indicated by the experiments with HERG ⌬C and HERG ⌬Cϩ104 , which demonstrate that a domain near the 3Ј-end of the mRNA, absent in HERG USO , is required for recapitulation of I Kr .
When HERG 1 and HERG USO were coexpressed in equimolar concentrations, there was no obvious effect on HERG 1 -mediated current (I Kr ). The finding that mRNA transcripts encoding HERG USO were much more abundant than those for HERG 1 suggested testing the effect of excess HERG USO as a next step in these experiments. This approach resulted in currents that demonstrated gating properties quite different from those seen with expression of HERG 1 alone. This finding strongly suggests that the two isoforms coassemble to form heterotetrameric channels, although direct biochemical evidence of such coassembly in heterologous systems, and ultimately in native tissues, will be required to further test this postulate. We reconstituted our partial HERG USO cDNA with the N terminus from HERG 1 because Spector et al. (7) have previously shown that a deletion of amino acids 2-354 of HERG 1 did not affect activation or fast inactivation of the resulting I Kr , although the voltage dependence of activation and inactivation were shifted by ϩ20 to ϩ30 mV, and the rate of deactivation was much faster with the truncation mutant than with the wild-type channel (7) . Similar results with a N-terminal deletion mutant, from amino acids 2-373, have also been reported by Schonherr and Heinemann (30) .
We consider that experiments using heterologous expression approaches that demonstrate only small changes in ion channel function cannot be interpreted with any confidence. Therefore, we used a 1:10 HERG 1 :HERG USO ratio when experiments with the 1:1 ratio did not produce an obvious change current amplitude or gating. If we assume that the two RNAs are translated with equal efficiency and have equal opportunity to assemble with other subunits, the incidence of homotetrameric HERG 1 complexes formed by the 1:10 ratio of RNAs will be vanishingly small ( 1 ⁄14,641, or Ͻ0.01%). Thus, the result in Fig.  3B indicates that heterotetrameric HERG 1 /HERG USO channels can recapitulate I Kr (or that the assumptions of equivalent translation and synthesis are incorrect). Given the assumptions inherent in interpreting this sort of experiment, we believe that the most appropriate interpretation is that expression HERG USO modifies HERG 1 amplitude and gating in the human heart but that the extent of this interaction in situ remains uncertain. Fig. 3, A and B) . C, time constants for activation (fast (Ⅺ) and slow (E) components were derived from Ϫ10 to ϩ30 mV, whereas a single component (‚) was sufficient at ϩ40 to ϩ60 mV). HERG ⌬Cϩ104 resulted in typical I Kr in the absence of the CNB domain, thereby establishing that the CNB domain is not required for I Kr expression. Furthermore, C-terminal variants lacking the 104-amino acid domain at positions 1018 -1122 (HERG ⌬C and HERG USO ) expressed no I Kr , whereas the HERG ⌬Cϩ104 rescue construct, which included this domain at the 3Ј-end, did. The requirement for this domain provides an explanation for the presumed defect in repolarizing current in LQT2 mutations reported in the 3Ј-end of the gene, at the nt 2398 splice site and beyond (10, 20) .
The function of the 104-amino acid domain that we have implicated as essential for recapitulation of I Kr is not yet understood. One possibility is that it is required to allow for the assembly for HERG protein tetramers. One previous report (17) has implicated a protein domain from the N terminus of HERG in the assembly of HERG homotetramers. However, N-terminal truncations of HERG do result in current (7), indicating that the N-terminal domain is not required, at least not on all four subunits of the presumed tetrameric channel.
Recent studies with rat eag (21) , with the plant potassium channel AKT1 (22) , and with KCNQ2 (23) have implicated regions of the respective C termini in subunit-subunit interactions that are crucial to generation of potassium current. The same may thus hold true for the C-terminal 104-amino acid domain that we have identified in HERG 1 , although the specific function (e.g. assembly or trafficking) is uncertain. We cannot rule out the possibility that this domain interacts with other proteins; indeed, we and others have suggested that the minK protein interacts with HERG to increase I Kr (26, 31) . Finally, the effect of HERG USO may be exerted not at the protein level but at the RNA level; production of the alternatively spliced HERG USO isoform could regulate the amount of and/or the processing and translation of HERG 1 mRNA. This could be accomplished by competition for necessary transcription factors that are present in limiting amounts or competition for components of the splicing machinery. Such competition could then serve to limit the amount of functional HERG 1 protein produced and might assume importance in acquired diseases associated with perturbations of cardiac repolarization. In this regard, it is of interest that splice variants of mRNA encoding glutamate transporters, including an intronretention event, have recently been reported in amyotrophic lateral sclerosis (32) . Along these lines, in preliminary studies, we have found that transcripts encoding HERG 1 mRNA are unchanged in hearts from patients with advanced cardiac failure but that those encoding HERG USO are decreased by ϳ50% (33).
